How Pfizer thinks about AI, Thomson 1.0, & Who's Behind Ox Alpha? | 150
Send us Fan Mail
A drug company CEO just made the best case yet for why platform choice matters less than most associations think. Marking three years of Sidecar Sync, Amith Nagarajan and Mallory Mejias dig into Pfizer's new playbook for organizing around AI, Thomson Reuters' $40 million bet on building its own legal model instead of renting one, and the six-day mystery of Ox Alpha, an anonymous coding model that became OpenRouter's biggest launch ever. They trace Pfizer CEO Albert Bourla's three moves — structuring data, federating decisions, and building AI fluency — and translate each for…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.